Nectin-4-Targeted PET Tracer [68Ga]Ga-FZ-NR-1 Outperforms FDG in Recurrent or Metastatic Triple-Negative Breast Cancer
核心洞察
A Fudan University Shanghai Cancer Center study found the Nectin-4 (搜索)-targeted tracer [68Ga]Ga-FZ-NR-1 (搜索) detected more lesions than FDG PET/CT in recurrent or metastatic triple-negative breast cancer (搜索).
The tracer achieved 98.13 percent sensitivity and 68.63 percent specificity versus 93.46 percent and 27.45 percent for FDG in a head-to-head comparison of 40 patients.
Baseline Nectin-4 (搜索) scan parameters predicted outcomes, with high mean MTV40 linked to shorter progression-free survival (P=0.009) and a high heterogeneity index to shorter overall survival (P=0.008).
A gallium-68-labeled radioligand that binds the tumor surface molecule Nectin-4 (搜索) detected more lesions and produced sharper tumor-to-background contrast than standard FDG PET/CT in patients with recurrent or metastatic triple-negative breast cancer (搜索), according to a clinical translational study published in the European Journal of Nuclear Medicine and Molecular Imaging.
The tracer, [68Ga]Ga-FZ-NR-1 (搜索), was evaluated by a team at Fudan University Shanghai Cancer Center in 40 patients with recurrent or metastatic triple-negative breast cancer (搜索). Each participant underwent both [68Ga]Ga-FZ-NR-1 PET/CT and conventional FDG PET/CT within a single week, a head-to-head design that allowed direct comparison of the two tracers in the same patients, the same lesions, and at the same time points. Diagnostic performance was assessed against a reference standard and compared statistically using the McNemar test, while survival outcomes were analyzed with Kaplan-Meier methods.
Diagnostic Performance and Contrast
On raw signal intensity, FDG retained an advantage: the study found that FDG achieved higher maximum standardized uptake values (SUVmax), reflecting the intense glucose consumption typical of aggressive cancers. The new tracer, however, delivered a significantly higher tumor-to-background ratio across a variety of metastatic sites. Because Nectin-4 (搜索) is minimally expressed in normal adult tissues, the tracer produces high contrast against a quiet background, whereas FDG competes with physiological glucose uptake in the brain, heart, bowel, and inflamed tissue.
The diagnostic numbers favored the Nectin-4 (搜索) tracer. [68Ga]Ga-FZ-NR-1 (搜索) PET/CT detected more lesions overall than FDG PET/CT and achieved a sensitivity of 98.13 percent compared with 93.46 percent for FDG. The difference in specificity was larger: 68.63 percent for the Nectin-4 tracer versus 27.45 percent for FDG. In practical terms, uptake on the Nectin-4 scan was far more likely to represent genuine malignancy rather than a benign mimic — a distinction of particular value in recurrent disease, where scar tissue from prior surgery and radiation can confound interpretation.
Mapping Tumor Heterogeneity
The study also quantified spatial variability of Nectin-4 (搜索) expression across lesions within individual patients. The median inter-lesion fold difference in uptake was 3.10, and the median coefficient of variation reached 31.70 percent, meaning one metastatic deposit might show intense uptake while another lesion in the same patient barely registered.
That finding carries direct therapeutic implications for antibody-drug conjugates, which depend on target expression at every disease site. A tumor clone that has downregulated Nectin-4 (搜索) could survive treatment and seed relapse even when the primary lesion shows abundant target — biology that a single biopsy cannot capture but that whole-body PET mapping can render visible.
Prognostic Signal From a Single Baseline Scan
Beyond diagnosis, the researchers measured volumetric and heterogeneity parameters from baseline Nectin-4 (搜索) scans, including metabolic tumor volume at a 40 percent threshold (MTV40) and a heterogeneity index (HI). Patients with a high baseline mean MTV40 on the Nectin-4 scan had significantly shorter progression-free survival (P=0.009), while a high heterogeneity index predicted significantly shorter overall survival (P=0.008). These associations suggest that the burden of Nectin-4-expressing disease and the unevenness of its expression are quantitative signals of aggressive biology that could help stratify patients before therapy begins.
Context in Nectin-4-Directed Therapy
Nectin-4 (搜索) is a cell adhesion molecule largely silenced in healthy adult tissue but overexpressed in a range of malignancies, including triple-negative breast cancer (搜索), where it has been linked to proliferation, metastasis, and poor prognosis. Its clinical relevance has been underscored by enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate approved for urothelial carcinoma, and by a growing pipeline of next-generation Nectin-4-targeted agents in development across solid tumors.
Companion diagnostics have become increasingly important as antibody-drug conjugates multiply, because these expensive and sometimes toxic drugs work best in patients whose tumors express the target. Immunohistochemistry on a biopsy offers only a local, single-site answer, and studies in urothelial carcinoma have shown that Nectin-4 (搜索) expression can decrease during metastatic spread, contributing to resistance against enfortumab vedotin. A whole-body PET tracer offers a complementary, dynamic view: confirming target expression across every known lesion, quantifying heterogeneity, and potentially identifying patients most likely to benefit from Nectin-4-directed treatment.
Caveats and Next Steps
The authors describe their findings as hypothesis-generating. The study involved 40 patients at a single institution, and the survival analyses, while statistically significant, require validation in larger, multicenter cohorts before they can guide clinical decision-making. The comparison also reflects the specific tracer and imaging protocols used, and questions remain about optimal timing, dosimetry, and how Nectin-4 (搜索) PET findings should be integrated with existing staging tools. Cost and availability of gallium-68 radiopharmaceutical production will also shape adoption, although generator-based production and the expanding network of radiopharmacies are steadily lowering those barriers.
Triple-negative breast cancer (搜索) lacks the estrogen, progesterone, and HER2 receptors that make other breast cancers vulnerable to targeted drugs, and it tends to relapse early, spread aggressively, and resist conventional chemotherapy. For patients whose disease has returned or metastasized, FDG PET/CT has long been the standard, but glucose metabolism is a blunt instrument: inflamed tissue, healing wounds, and infections can all produce uptake, and some metabolically quiet tumors escape detection entirely. The Fudan team's work positions [68Ga]Ga-FZ-NR-1 (搜索) as both a diagnostic upgrade and a prognostic instrument, a dual role that mirrors the theranostic approach increasingly shaping nuclear medicine.